Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00927784 · ClinicalTrials.gov registry record · Phase 2
Effect of Intramyocardial Injection of Mesenchymal Precursor Cells on Heart Function in People Receiving an LVAD
A Phase 2 study, sponsored by Icahn School of Medicine at Mount Sinai.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT00927784 is a Phase 2 study that was terminated before completion, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 10 participants.
The verdict
NCT00927784, a Phase 2 study, was terminated before completion, sponsored by Icahn School of Medicine at Mount Sinai.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
Left ventricular assist devices (LVADs) are one treatment option for people with congestive heart failure. This study will evaluate the safety of injecting mesenchymal precursor cells (MPCs) into the heart during LVAD implantation surgery and examine if injecting MPCs into the heart is effective at improving heart function.
Interventions
- BIOLOGICAL Mesenchymal Precursor cells (RevascorTM)
- DRUG Cryoprotective media alone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2009-08 |
| Est. Completion | 2011-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00927784
The ClinicalTrials.gov registry entry for NCT00927784 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Mesenchymal Precursor cells (RevascorTM) is the first listed.
NCT00927784 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00927784 about?
NCT00927784 is a clinical study titled "Effect of Intramyocardial Injection of Mesenchymal Precursor Cells on Heart Function in People Receiving an LVAD". Left ventricular assist devices (LVADs) are one treatment option for people with congestive heart failure. This study will evaluate the safety of injecting mesenchymal precursor cells (MPCs) into the heart during LVAD implantation surgery and examine if injecting MPCs into the heart is effective at ...
What is the current status of trial NCT00927784?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2009-08. Estimated completion is 2011-02.
What interventions are being tested in trial NCT00927784?
The interventions under investigation include: Mesenchymal Precursor cells (RevascorTM) (BIOLOGICAL), Cryoprotective media alone (DRUG).
Who is sponsoring clinical trial NCT00927784?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.